TALMINEX (Accelagen Pty Ltd)
Product name
TALMINEX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
163 working days (255)
Active ingredients
oseltamivir phosphate
Registration type
New generic medicine
Indication
TALMINEX (capsules) is indicated for the treatment of infections due to influenza A and B viruses in adults and children including full-term neonates. Treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.
TALMINEX is indicated for the prevention of influenza in adults and children aged 1 year and older. Vaccination is the preferred method of routine prophylaxis against infection with influenza virus.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine